Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-glucans in Hospitalised COVID-19 Patients
NCT05465798Phase 2Unknown
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of MC 3x3 in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Intensity of clinical symptoms (WURSS-21 scores) at 7 days, Duration of symptoms up to 2 weeks and 1 more. Status: unknown.
02
Drugs
MC 3x3
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05465798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465798.